Sign in

Digital Jagran

Information, Information and Information

  1. Home
  2. /
  3. Biotech
  4. /
  5. Avalyn targets $182 million IPO to advance inhaled respiratory therapies
Back to News
Biotech

Avalyn targets $182 million IPO to advance inhaled respiratory therapies

Avalyn Pharma plans a $182 million IPO to fund late-stage trials of inhaled therapies for lung diseases, including treatments for pulmonary fibrosis.

S
Surya Pratap Singh
4/27/2026, 5:56:15 AM
Avalyn targets $182 million IPO to advance inhaled respiratory therapies
Share
0 min read

Digital Jagran

Your trusted source for the latest news, in-depth analysis, and perspectives from India and around the world — in both Hindi and English.

Sections

  • Politics
  • World
  • Business
  • Technology
  • Sports
  • Entertainment

Company

  • About Us
  • Contact Us
  • Privacy Policy
  • Terms of Service
  • Disclaimer

Subscribe

Stay updated with the latest news delivered to your inbox.

© 2026 Digital Jagran. All rights reserved.

PrivacyTermsDisclaimerContact
Home